MRK stock forecast, quote, news & analysis

Key Takeaways

• Merck & Co. (MRK) traded near $148 in late October 2026, roughly flat over the trailing 30 days after a mid-session gain of about 3% in the latest session.
• Second-quarter 2026 revenue rose 5% to $16.6 billion, but a one-time Terns acquisition charge pushed reported results to a net loss.
• Keytruda remains the company's earnings engine at roughly $8.4 billion in quarterly sales, while Winrevair and Welireg delivered fast growth.
• Pipeline momentum, including sac-TMT, tulisokibart, and LIPFENDRA, is central to the investment narrative ahead of Keytruda's loss of exclusivity.
• Analyst commentary stayed constructive in October, with several firms adjusting price targets and ratings.

Current Market Snapshot

Merck & Co. shares have traded in a relatively narrow range over the past month, holding near the $148 level after recovering from an early-October pullback toward the low $140s. The stock is up more than 40% year to date, with a 52-week range spanning from roughly $82 to about $157, reflecting a sustained re-rating driven by pipeline progress and business development activity.

Within the healthcare sector, Merck occupies a defensive, large-cap position that has drawn steady institutional interest even as broader sentiment around pharmaceuticals ebbs and flows. The shares carry a consensus Buy rating from analysts, with an average target price near the mid-to-high $150s, suggesting the market is weighing near-term earnings noise against a longer-term diversification story.

Merck & Co. (MRK) Business Overview and Competitive Position

Merck & Co., Inc., headquartered in Rahway, New Jersey, and known as MSD outside the United States and Canada, is one of the world's largest pharmaceutical companies. Its business spans oncology, vaccines, cardiometabolic and respiratory medicine, immunology, and infectious disease, alongside a substantial animal health division.

The oncology franchise is anchored by Keytruda (pembrolizumab), one of the best-selling drugs globally, complemented by a growing portfolio that includes Welireg, Winrevair, and alliance products such as Lynparza. The vaccines segment is led by Gardasil and Gardasil 9, while newer launches including Capvaxive and Ohtuvayre are broadening revenue streams. Merck's competitive strengths include deep oncology leadership, a diversified late-stage pipeline, large-scale R&D and manufacturing capabilities, and a reliable dividend supported by durable cash flows.

Recent Developments Driving MRK

Several verified developments have shaped investor sentiment over the past month. In October, HSBC lifted its price target on the shares to $175 from $172, while Leerink Partners maintained a Buy rating with a $161 target. Barclays also issued a Buy, while RBC Capital reiterated a Hold, underscoring a mixed but broadly constructive analyst stance.

On the business-development front, Merck secured an exclusive global license for a preclinical KRAS G12D inhibitor from SciBrunch Therapeutics, deepening its targeted-oncology capabilities. The company also voluntarily withdrew its U.S. application for ifinatamab deruxtecan in small cell lung cancer following regulatory feedback, though late-stage studies continue. In vaccines, Ontario added Capvaxive to its publicly funded adult pneumococcal immunization program.

Longer-term governance and pipeline signals also featured, including the appointment of Paul J. Diaz to the board and preparations to present Phase 3 melanoma data tied to Merck's personalized cancer program with Moderna. Separately, a Dutch court ruling ordered a halt to sales of a subcutaneous Keytruda formulation in several European markets amid a patent dispute, a development Merck is contesting.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of the platform's most relevant and top-performing AI-driven trading bots. Tickeron offers hundreds of bots trading thousands of tickers, but only those demonstrating standout performance and relevance appear in this featured section. The bots vary considerably in strategy, holding timeframe, and performance metrics, allowing traders to review different approaches before acting. The section is designed to help users identify automated strategies aligned with their own objectives, and it serves as a practical starting point for exploring how AI-powered systems approach markets like MRK.

2026 Outlook and What Investors Should Watch

Looking ahead, the most important near-term catalyst is Merck's third-quarter earnings report, expected in late October 2026, which will clarify launch trajectories for Winrevair, Welireg, Ohtuvayre, and LIPFENDRA. Management has guided 2026 revenue to a range of $66.3 billion to $67.3 billion, with non-GAAP EPS of $2.66 to $2.76 reflecting substantial acquisition-related charges.

The central long-term theme remains the approaching Keytruda loss of exclusivity, expected between 2028 and 2030, and whether newer franchises can offset that decline. Investors will monitor pivotal readouts across the TroFuse (sac-TMT) program, tulisokibart in inflammatory disease, and oral PCSK9 therapy LIPFENDRA, as well as the HIV combination work with Gilead. Regulatory, patent-litigation, and macroeconomic risks, together with M&A execution, will continue to shape the stock's trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations